High Lipoprotein(a) Symptoms: What Elevated Lp(a) Means for Your Heart Health

Quick answer: High lipoprotein(a) — also written as Lp(a) — does not produce recognizable symptoms on its own. Elevated Lp(a) is a silent cardiovascular risk factor that increases the likelihood of heart attack, stroke, and aortic valve disease independent of LDL cholesterol. Because it is largely genetically determined and often missed on standard lipid panels, many people with elevated Lp(a) remain unaware of it until a cardiac event occurs.

What is Lipoprotein(a) and Why Does it Matter?

Lipoprotein(a), or Lp(a), is a lipoprotein particle structurally similar to LDL cholesterol but with an additional protein called apolipoprotein(a) attached. This structural difference makes Lp(a) more atherogenic than standard LDL: it promotes plaque formation in arterial walls, interferes with clot breakdown (fibrinolysis), and may accelerate calcification of the aortic valve (EAS consensus on Lp(a) in cardiovascular disease).

Lp(a) concentration is predominantly determined by genetics, with the LPA gene accounting for the majority of variation between individuals. Diet, exercise, and most lipid-lowering medications have minimal effect on Lp(a) levels (Lp(a) is genetically determined). This is what makes it clinically distinct from LDL cholesterol: you cannot meaningfully lower it through lifestyle modification alone, and a person with optimal diet and exercise habits can still carry significantly elevated Lp(a).

A 2022 JAMA Cardiology review established Lp(a) as an independent causal risk factor for atherosclerotic cardiovascular disease, and a landmark 30-year Women's Health Study published in the New England Journal of Medicine found that elevated Lp(a), combined with high LDL and CRP, strongly predicted cardiovascular events over three decades.

Why Elevated Lp(a) Usually Has No Symptoms

Lp(a) contributes to cardiovascular risk by gradually promoting atherosclerosis, the buildup of plaque inside arterial walls. Atherosclerosis is a slow, largely silent process. Most people with elevated Lp(a) will not experience any symptoms related to it for years or decades. When symptoms do appear, they typically reflect the consequences of cardiovascular disease rather than Lp(a) elevation itself.

This is the defining clinical challenge of Lp(a): its effects are real and well-documented, but they manifest only after arterial damage has accumulated. Testing is the only way to identify elevated Lp(a) before a cardiovascular event occurs.

Conditions Associated with Elevated Lp(a)

Premature cardiovascular disease

One of the strongest clinical associations with elevated Lp(a) is cardiovascular disease occurring earlier than expected, particularly in individuals who otherwise appear to have a favorable risk profile. People who experience a heart attack before age 55 (men) or 65 (women) with normal LDL cholesterol and no conventional risk factors are frequently found to have elevated Lp(a) when tested (Lp(a) in premature cardiovascular disease). A multi-ethnic prospective cohort published in the Journal of the American College of Cardiology (2024) confirmed that Lp(a) independently predicts long-term cardiovascular events across diverse populations.

Aortic valve stenosis

Elevated Lp(a) is specifically associated with calcific aortic valve disease (Lp(a) and calcific aortic valve stenosis review), a condition where calcium deposits narrow the aortic valve opening and restrict blood flow from the heart. Symptoms of aortic valve stenosis (chest pain, shortness of breath, dizziness on exertion) may be the first clinical indication of elevated Lp(a) in some individuals, though the valve disease develops over many years before producing symptoms. This association is stronger for Lp(a) than for LDL or standard lipid markers.

Stroke and peripheral arterial disease

Elevated Lp(a) is associated with increased risk of ischemic stroke and peripheral arterial disease (PAD) (Lp(a) risk for coronary, cerebrovascular, and peripheral disease), which can produce symptoms including leg pain during walking (claudication) and impaired wound healing in the extremities. These conditions reflect generalized atherosclerosis that Lp(a) contributes to alongside other cardiovascular risk factors.

Family history of early heart disease

Because Lp(a) levels are predominantly genetic, elevated Lp(a) tends to cluster within families. A first-degree relative (parent or sibling) who experienced a heart attack or stroke before age 60, particularly without conventional risk factors such as smoking or poorly controlled hypertension, increases the probability that elevated Lp(a) is contributing to familial cardiovascular risk.

Understanding Lp(a) Test Results

Lp(a) is measured in either milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L), and these units are not interchangeable. The European Atherosclerosis Society considers Lp(a) levels above 50 mg/dL (approximately 125 nmol/L) to represent high risk (EAS Lp(a) risk thresholds), though there is an approximately linear relationship between Lp(a) concentration and cardiovascular risk across the full distribution. Prospective cohort data confirms that risk increases progressively with Lp(a) concentration, with no clear threshold below which Lp(a) contributes no additional risk.

Reference ranges vary by laboratory and assay method. Your provider will interpret your specific result in the context of your overall cardiovascular risk profile. It is also important to note the units reported, as the same numerical value in mg/dL versus nmol/L carries very different clinical meaning.

Which Biomarkers Are Worth Testing Alongside Lp(a)?

Because Lp(a) contributes to cardiovascular risk alongside other lipid and inflammatory markers, testing it in context with a broader cardiovascular panel provides the most complete picture.

• Lipoprotein(a) — Genetically elevated cardiovascular risk particle; independent of LDL
• LDL cholesterol — Standard atherogenic lipoprotein; elevated LDL multiplies Lp(a) risk
• Apolipoprotein B (ApoB) — Total atherogenic particle count; superior to LDL-C for risk assessment
• hs-CRP — Systemic inflammation; combined with Lp(a) and LDL in landmark 30-year risk study
• LDL particle size and number — Particle-level cardiovascular risk beyond LDL-C concentration

Superpower's Baseline Blood Panel includes Lp(a), ApoB, LDL, and HDL. For a fuller cardiovascular picture including particle size and ADMA/SDMA (markers of vascular function), Superpower's Cardiovascular Panel provides a comprehensive assessment.

What Can Be Done about Elevated Lp(a)?

This article does not constitute medical advice, and elevated Lp(a) requires provider evaluation. From an informational standpoint: standard lipid-lowering medications such as statins have minimal effect on Lp(a). PCSK9 inhibitors have been shown to modestly reduce Lp(a) levels, with FOURIER trial data suggesting this reduction contributes to reduced cardiovascular events. Novel RNA-based therapies targeting Lp(a) specifically are in late-stage clinical trials. In the meantime, managing total cardiovascular risk through LDL control, blood pressure, inflammation, and metabolic health is the primary clinical approach.

When to Talk to a Doctor about Lp(a)

Lp(a) testing is particularly relevant if you have a family history of premature heart disease, have experienced a cardiovascular event despite normal LDL cholesterol, or have been told you have aortic valve disease. The European Atherosclerosis Society recommends that every adult have Lp(a) tested at least once (EAS consensus recommends universal Lp(a) testing), as a single measurement provides useful lifetime risk context given its genetic stability.

Frequently Asked Questions

What are the warning signs of high Lp(a)?

There are no specific symptoms caused by elevated Lp(a) itself. Lp(a) increases cardiovascular risk silently over time. Warning signs of the consequences, such as angina (chest pain on exertion), shortness of breath, or leg pain while walking, reflect cardiovascular disease that Lp(a) may have contributed to rather than the elevated Lp(a) directly.

Is high Lp(a) hereditary?

Yes. Lp(a) levels are predominantly determined by variation in the LPA gene and are largely inherited. A person with one parent who has high Lp(a) has a substantially elevated probability of having elevated Lp(a) themselves. This is why family history of premature heart disease is a key indicator for Lp(a) testing.

Does diet affect Lp(a) levels?

Diet has minimal effect on Lp(a) concentration. Unlike LDL cholesterol, which responds meaningfully to dietary fat and fiber intake, Lp(a) is primarily determined by genetics and is largely resistant to dietary modification. This distinguishes it from most other cardiovascular risk markers and underscores the importance of testing rather than assuming diet controls it.

Is Lp(a) included in a standard cholesterol test?

No. Standard lipid panels (total cholesterol, LDL, HDL, triglycerides) do not include Lp(a). It must be ordered as a separate test or as part of a comprehensive cardiovascular panel. Many individuals with significantly elevated Lp(a) remain unaware because it has never been measured.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine. Superpower offers blood panels that include the biomarkers discussed in this article. Links to individual tests are provided for informational context.